Effect of Apolipoprotein E Polymorphism on Serum Uric Acid Levels in Healthy Subjects
暂无分享,去创建一个
M. Elisaf | E. Bairaktari | V. Athyros | E. Liberopoulos | G. Miltiadous | M. Cariolou | M. Ganotakis
[1] D. Mikhailidis,et al. Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies , 2004 .
[2] M. Elisaf,et al. The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] M. Elisaf,et al. Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[4] M. Elisaf,et al. Alcohol intake, serum uric acid concentrations, and risk of gout , 2004, The Lancet.
[5] M. Austin,et al. Heritability of C‐Reactive Protein and Association with Apolipoprotein E Genotypes in Japanese Americans , 2004, Annals of human genetics.
[6] M. Elisaf,et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] M. Elisaf,et al. Apolipoprotein E polymorphism in northwestern Greece: frequency and effect on lipid parameters. , 2004, Annals of clinical and laboratory science.
[8] S. Daskalopoulou,et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. , 2004, Kidney international.
[9] M. Elisaf,et al. Apolipoprotein E and renal disease. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] M. Elisaf,et al. Could apolipoprotein E polymorphisms be hidden behind the relation between bone mineral density and atherosclerosis in hemodialysis patients? , 2003, Osteoporosis International.
[11] K. Cianflone,et al. ApoE phenotype influences plasma ASP in hyperapoB subjects. , 2003, Atherosclerosis.
[12] Andrea Mari,et al. Methods for clinical assessment of insulin sensitivity and β-cell function , 2003 .
[13] F. Tinahones,et al. The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. , 2003, Rheumatology.
[14] M. Elisaf,et al. The Effects of the Addition of Micronised Fenofibrate on Uric Acid Metabolism in Patients Receiving Indapamide , 2002, Current medical research and opinion.
[15] A. J. Maxwell,et al. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. , 2001, Journal of the American College of Cardiology.
[16] M. Elisaf,et al. Evaluation of five methods for determining low-density lipoprotein cholesterol (LDL-C) in hemodialysis patients(1). , 2001, Clinical biochemistry.
[17] L. Ruilope,et al. Hyperuricemia and renal function , 2001, Current hypertension reports.
[18] D. Singer,et al. Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: the Framingham Offspring Study. , 2000, Diabetes care.
[19] M. Grazina,et al. Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. , 1999, International journal of molecular medicine.
[20] P. Sánchez-Guijo,et al. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. , 1997, The Journal of clinical endocrinology and metabolism.
[21] A. Saeki,et al. [Hyperuricemia and insulin resistance]. , 1996, Nihon rinsho. Japanese journal of clinical medicine.
[22] F. Tinahones,et al. Increased VLDL levels and diminished renal excretion of uric acid in hyperuricaemic-hypertriglyceridaemic patients. , 1995, British journal of rheumatology.
[23] J. Dallongeville,et al. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. , 1992, Journal of lipid research.
[24] G. Reaven,et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. , 1991, JAMA.
[25] D. T. Vernier,et al. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.
[26] Y. Matsuzawa,et al. Relationship between hypertriglyceridemia and uric acid production in primary gout. , 1989, Metabolism: clinical and experimental.
[27] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[28] C. Ehnholm,et al. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. , 1987, The Journal of clinical investigation.
[29] G. Utermann,et al. Apolipoprotein E polymorphism in health and disease. , 1987, American heart journal.
[30] E. Collantes Estévez,et al. Renal excretion of urate by hyperuricaemic-hyperlipidemic patients. , 1992, Clinical rheumatology.
[31] R. Terkeltaub,et al. Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. , 1991, The Journal of clinical investigation.
[32] R. Gregg,et al. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans. , 1988, Clinical chemistry.
[33] Brewer Hb,et al. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in humans. , 1988 .